FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D C	20540
wasnington,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LIDDY EDWARD M</u>						2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ ABBV ]								Relationship of Reporting Pers (Check all applicable)     X Director				son(s) to Iss		
(Last) (First) (Middle) 1 N. WAUKEGAN ROAD				3. Date of Earliest Transaction (Month/Day/Year) 12/31/2020									Officer below)	(give title		Other (s below)	pecify			
(Street) NORTH CHICAC			50064 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								3. Indi ∟ine) X	-/					
		Tabl	e I - Nor	n-Deriv	ative	Sec	curitie	es Ac	quired,	Dis	osed o	of, or Be	nefic	ially	Owned	d t				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					ction 2A. Deemed Execution Date,			Code (I	3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)				4 and Securiti Benefic Owned		es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
					Code V		v	Amount	mount (A) or (D)		е	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,		ransaction ode (Instr.		ı of		6. Date Exercisabl Expiration Date (Month/Day/Year)		Amount of		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	or	Number of						
Stock Equivalent Units	\$0 <sup>(1)</sup>	12/31/2020			A		314		(1)		(1)	Common Stock	314		\$107.15	27,440 <sup>(</sup>	2)	D		

## **Explanation of Responses:**

- 1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from AbbOtie's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Steven L. Scrogham, attorneyin-fact for Edward M. Liddy

01/05/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.